Subtle Medical has received U.S. Food and Drug Administration clearance for SubtleHD™ (PET), a next-generation AI-powered image enhancement solution built to sharpen positron emission tomography (PET) scans and speed up imaging workflows. Announced on May 27, 2026 from Menlo Park, California, the clearance expands the company's reach into one of the fastest-growing corners of molecular imaging.
What SubtleHD (PET) does
The software is designed to improve image quality and accelerate PET imaging across both PET/CT and PET/MR systems. According to the company, SubtleHD (PET) enables up to 75% faster PET imaging on existing scanners, allowing hospitals to raise throughput without buying new hardware. Built on a state-of-the-art AI model architecture, it delivers improved image enhancement performance and greater SUVmax quantitation accuracy, a measure that clinicians rely on when tracking tumors and treatment response.
Crucially, the tool is compatible with all FDA-approved radiotracers, including emerging molecular imaging agents beyond traditional 18F-FDG. It was validated across a broad range of accelerated, low-count PET acquisitions and lets radiologists adjust the denoising level to their preference. The system also leverages anatomical CT data to further improve PET image reconstruction quality and quantitative consistency.
Why it matters for hospitals
There are an estimated 4.5 million PET scans performed each year globally, and demand keeps rising as new tracers and theranostic workflows emerge. Subtle Medical cited industry data showing that 67% of PET imaging sites expect procedure volumes to grow over the next 12 months. As volumes climb, health systems face mounting pressure to improve throughput, expand patient access and squeeze more value from existing scanner capacity and on-site cyclotrons.
"PET imaging demand continues to grow globally, but providers remain constrained by scanner capacity, long scan times, and operational inefficiencies," said Ajit Shankaranarayanan of Subtle Medical. He said SubtleHD (PET) brings the latest advances in AI imaging to help providers improve throughput, drive new revenue and maximize the value of existing PET infrastructure while delivering faster, more comfortable scans for patients.
Building on SubtlePET
The clearance builds on the company's earlier SubtlePET™ product, which is already deployed on numerous scanners worldwide. The push reflects a broader wave of regulatory wins for clinical AI, from the first FDA nod for an AI sepsis monitoring system to new approvals for surgical platforms such as the Cornerstone Robotics Sentire system in Europe. AI is also moving deeper into the operating room, including MRI-guided neurosurgery robotics developed with Siemens Healthineers.
The patient angle
For patients, shorter PET exams may reduce discomfort and improve the imaging experience, an advantage that is especially meaningful for oncology, elderly, pediatric and critically ill populations who can struggle to stay still through long scans. By trimming scan times while preserving diagnostic quality, AI enhancement tools like SubtleHD (PET) aim to make a high-value but resource-intensive test more widely accessible.
Reporting based on coverage from Subtle Medical via PR Newswire.